Electrophysiologic drug testing in prophylaxis of sporadic paroxysmal atrial fibrillation: Technique, application, and efficacy in severely symptomatic preexcitation patients
Identifieur interne : 001559 ( Main/Corpus ); précédent : 001558; suivant : 001560Electrophysiologic drug testing in prophylaxis of sporadic paroxysmal atrial fibrillation: Technique, application, and efficacy in severely symptomatic preexcitation patients
Auteurs : Robert A. Bauernfeind ; Steven P. Swiryn ; Boris Strasberg ; Edwin Palileo ; Daniel Scagliotti ; Kenneth M. RosenSource :
- American Heart Journal [ 0002-8703 ] ; 1982.
Abstract
Electrophysiologic drug testing was performed in nine patients with severely symptomatic sporadic (2 to 13 [mean 4.2] attacks/24 months) paroxysmal atrial fibrillation (PAF). All patients had control inductions of sustained (> 30 seconds) AF by high right atrial stimulation, and attempted inductions following serial administration of drugs. Drugs tested were intravenous procainamide (1.0 to 1.5 gm) (five patients), intravenous propranolol (0.1 mg/kg) (three patients), oral quinidine (1.6 to 2.4 gm/day) (six patients), oral disopyramide (1.2 to 1.6 gm/day) (four patients), and oral aprindine (100 to 250 mg/day) (four patients). In all patients, one or more drugs prevented induction of sustained AF: procainamide (one patient), quinidine (five patients), disopyramide (four patients), and aprindine (four patients). All patients were treated with drugs which prevented induction of sustained AF and followed for 8 to 40 (mean 24) months. Seven patients tolerated their drugs: six had no AF and one had several short nonsustained attacks. Two patients did not tolerate their drugs: one had paroxysmal palpitation (on decreased aprindine dosage), and one had AF (while off of aprindine). In conclusion, electrophysiologic drug testing is feasible in patients with sporadic PAF. Inability to induce sustained AF following drug administration suggests successful prophylaxis of spontaneous PAF with the same drug.
Url:
DOI: 10.1016/0002-8703(82)90555-5
Links to Exploration step
ISTEX:AE57E87DD3019AB099536DAB0AE539D3B5080899Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Electrophysiologic drug testing in prophylaxis of sporadic paroxysmal atrial fibrillation: Technique, application, and efficacy in severely symptomatic preexcitation patients</title><author><name sortKey="Bauernfeind, Robert A" sort="Bauernfeind, Robert A" uniqKey="Bauernfeind R" first="Robert A." last="Bauernfeind">Robert A. Bauernfeind</name><affiliation><mods:affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</mods:affiliation></affiliation></author><author><name sortKey="Swiryn, Steven P" sort="Swiryn, Steven P" uniqKey="Swiryn S" first="Steven P." last="Swiryn">Steven P. Swiryn</name><affiliation><mods:affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</mods:affiliation></affiliation></author><author><name sortKey="Strasberg, Boris" sort="Strasberg, Boris" uniqKey="Strasberg B" first="Boris" last="Strasberg">Boris Strasberg</name><affiliation><mods:affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</mods:affiliation></affiliation></author><author><name sortKey="Palileo, Edwin" sort="Palileo, Edwin" uniqKey="Palileo E" first="Edwin" last="Palileo">Edwin Palileo</name><affiliation><mods:affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</mods:affiliation></affiliation></author><author><name sortKey="Scagliotti, Daniel" sort="Scagliotti, Daniel" uniqKey="Scagliotti D" first="Daniel" last="Scagliotti">Daniel Scagliotti</name><affiliation><mods:affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</mods:affiliation></affiliation></author><author><name sortKey="Rosen, Kenneth M" sort="Rosen, Kenneth M" uniqKey="Rosen K" first="Kenneth M." last="Rosen">Kenneth M. Rosen</name><affiliation><mods:affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AE57E87DD3019AB099536DAB0AE539D3B5080899</idno><date when="1982" year="1982">1982</date><idno type="doi">10.1016/0002-8703(82)90555-5</idno><idno type="url">https://api.istex.fr/document/AE57E87DD3019AB099536DAB0AE539D3B5080899/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001559</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Electrophysiologic drug testing in prophylaxis of sporadic paroxysmal atrial fibrillation: Technique, application, and efficacy in severely symptomatic preexcitation patients</title><author><name sortKey="Bauernfeind, Robert A" sort="Bauernfeind, Robert A" uniqKey="Bauernfeind R" first="Robert A." last="Bauernfeind">Robert A. Bauernfeind</name><affiliation><mods:affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</mods:affiliation></affiliation></author><author><name sortKey="Swiryn, Steven P" sort="Swiryn, Steven P" uniqKey="Swiryn S" first="Steven P." last="Swiryn">Steven P. Swiryn</name><affiliation><mods:affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</mods:affiliation></affiliation></author><author><name sortKey="Strasberg, Boris" sort="Strasberg, Boris" uniqKey="Strasberg B" first="Boris" last="Strasberg">Boris Strasberg</name><affiliation><mods:affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</mods:affiliation></affiliation></author><author><name sortKey="Palileo, Edwin" sort="Palileo, Edwin" uniqKey="Palileo E" first="Edwin" last="Palileo">Edwin Palileo</name><affiliation><mods:affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</mods:affiliation></affiliation></author><author><name sortKey="Scagliotti, Daniel" sort="Scagliotti, Daniel" uniqKey="Scagliotti D" first="Daniel" last="Scagliotti">Daniel Scagliotti</name><affiliation><mods:affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</mods:affiliation></affiliation></author><author><name sortKey="Rosen, Kenneth M" sort="Rosen, Kenneth M" uniqKey="Rosen K" first="Kenneth M." last="Rosen">Kenneth M. Rosen</name><affiliation><mods:affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">American Heart Journal</title><title level="j" type="abbrev">YMHJ</title><idno type="ISSN">0002-8703</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1982">1982</date><biblScope unit="volume">103</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="941">941</biblScope><biblScope unit="page" to="949">949</biblScope></imprint><idno type="ISSN">0002-8703</idno></series><idno type="istex">AE57E87DD3019AB099536DAB0AE539D3B5080899</idno><idno type="DOI">10.1016/0002-8703(82)90555-5</idno><idno type="PII">0002-8703(82)90555-5</idno><idno type="ArticleID">82905555</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0002-8703</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Electrophysiologic drug testing was performed in nine patients with severely symptomatic sporadic (2 to 13 [mean 4.2] attacks/24 months) paroxysmal atrial fibrillation (PAF). All patients had control inductions of sustained (> 30 seconds) AF by high right atrial stimulation, and attempted inductions following serial administration of drugs. Drugs tested were intravenous procainamide (1.0 to 1.5 gm) (five patients), intravenous propranolol (0.1 mg/kg) (three patients), oral quinidine (1.6 to 2.4 gm/day) (six patients), oral disopyramide (1.2 to 1.6 gm/day) (four patients), and oral aprindine (100 to 250 mg/day) (four patients). In all patients, one or more drugs prevented induction of sustained AF: procainamide (one patient), quinidine (five patients), disopyramide (four patients), and aprindine (four patients). All patients were treated with drugs which prevented induction of sustained AF and followed for 8 to 40 (mean 24) months. Seven patients tolerated their drugs: six had no AF and one had several short nonsustained attacks. Two patients did not tolerate their drugs: one had paroxysmal palpitation (on decreased aprindine dosage), and one had AF (while off of aprindine). In conclusion, electrophysiologic drug testing is feasible in patients with sporadic PAF. Inability to induce sustained AF following drug administration suggests successful prophylaxis of spontaneous PAF with the same drug.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Robert A. Bauernfeind M.D.</name><affiliations><json:string>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</json:string></affiliations></json:item><json:item><name>Steven P. Swiryn M.D.</name><affiliations><json:string>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</json:string></affiliations></json:item><json:item><name>Boris Strasberg M.D.</name><affiliations><json:string>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</json:string></affiliations></json:item><json:item><name>Edwin Palileo M.D.</name><affiliations><json:string>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</json:string></affiliations></json:item><json:item><name>Daniel Scagliotti M.D.</name><affiliations><json:string>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</json:string></affiliations></json:item><json:item><name>Kenneth M. Rosen M.D.</name><affiliations><json:string>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Clinical investigation</value></json:item></subject><articleId><json:string>82905555</json:string></articleId><language><json:string>eng</json:string></language><abstract>Electrophysiologic drug testing was performed in nine patients with severely symptomatic sporadic (2 to 13 [mean 4.2] attacks/24 months) paroxysmal atrial fibrillation (PAF). All patients had control inductions of sustained (> 30 seconds) AF by high right atrial stimulation, and attempted inductions following serial administration of drugs. Drugs tested were intravenous procainamide (1.0 to 1.5 gm) (five patients), intravenous propranolol (0.1 mg/kg) (three patients), oral quinidine (1.6 to 2.4 gm/day) (six patients), oral disopyramide (1.2 to 1.6 gm/day) (four patients), and oral aprindine (100 to 250 mg/day) (four patients). In all patients, one or more drugs prevented induction of sustained AF: procainamide (one patient), quinidine (five patients), disopyramide (four patients), and aprindine (four patients). All patients were treated with drugs which prevented induction of sustained AF and followed for 8 to 40 (mean 24) months. Seven patients tolerated their drugs: six had no AF and one had several short nonsustained attacks. Two patients did not tolerate their drugs: one had paroxysmal palpitation (on decreased aprindine dosage), and one had AF (while off of aprindine). In conclusion, electrophysiologic drug testing is feasible in patients with sporadic PAF. Inability to induce sustained AF following drug administration suggests successful prophylaxis of spontaneous PAF with the same drug.</abstract><qualityIndicators><score>6.856</score><pdfVersion>1.3</pdfVersion><pdfPageSize>591.12 x 791.84 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>1</keywordCount><abstractCharCount>1416</abstractCharCount><pdfWordCount>4408</pdfWordCount><pdfCharCount>33210</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>204</abstractWordCount></qualityIndicators><title>Electrophysiologic drug testing in prophylaxis of sporadic paroxysmal atrial fibrillation: Technique, application, and efficacy in severely symptomatic preexcitation patients</title><pii><json:string>0002-8703(82)90555-5</json:string></pii><genre><json:string>research-article</json:string></genre><host><volume>103</volume><pii><json:string>S0002-8703(00)X0653-9</json:string></pii><pages><last>949</last><first>941</first></pages><issn><json:string>0002-8703</json:string></issn><issue>6</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><title>American Heart Journal</title><publicationDate>1982</publicationDate></host><publicationDate>1982</publicationDate><copyrightDate>1982</copyrightDate><doi><json:string>10.1016/0002-8703(82)90555-5</json:string></doi><id>AE57E87DD3019AB099536DAB0AE539D3B5080899</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/AE57E87DD3019AB099536DAB0AE539D3B5080899/fulltext/pdf</uri></json:item><json:item><original>true</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/AE57E87DD3019AB099536DAB0AE539D3B5080899/fulltext/txt</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/AE57E87DD3019AB099536DAB0AE539D3B5080899/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/AE57E87DD3019AB099536DAB0AE539D3B5080899/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Electrophysiologic drug testing in prophylaxis of sporadic paroxysmal atrial fibrillation: Technique, application, and efficacy in severely symptomatic preexcitation patients</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1982</date></publicationStmt><notesStmt><note>Supported in part by National Heart, Lung and Blood Institute Institutional Training Grant HL 07387 and by Research Grants HL 18794 and HL 23566, and by a grant from the Eleanor B. Pillsbury Resident Trust Fund.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Electrophysiologic drug testing in prophylaxis of sporadic paroxysmal atrial fibrillation: Technique, application, and efficacy in severely symptomatic preexcitation patients</title><author><persName><forename type="first">Robert A.</forename><surname>Bauernfeind</surname></persName><roleName type="degree">M.D.</roleName><note type="biography">Reprint requests: Robert A. Bauernfeind, M.D., Cardiology Section, University of Illinois Hospital, P.O. Box 6998, Chicago, IL 60680.</note><affiliation>Reprint requests: Robert A. Bauernfeind, M.D., Cardiology Section, University of Illinois Hospital, P.O. Box 6998, Chicago, IL 60680.</affiliation><affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</affiliation></author><author><persName><forename type="first">Steven P.</forename><surname>Swiryn</surname></persName><roleName type="degree">M.D.</roleName><affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</affiliation></author><author><persName><forename type="first">Boris</forename><surname>Strasberg</surname></persName><roleName type="degree">M.D.</roleName><affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</affiliation></author><author><persName><forename type="first">Edwin</forename><surname>Palileo</surname></persName><roleName type="degree">M.D.</roleName><affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</affiliation></author><author><persName><forename type="first">Daniel</forename><surname>Scagliotti</surname></persName><roleName type="degree">M.D.</roleName><affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</affiliation></author><author><persName><forename type="first">Kenneth M.</forename><surname>Rosen</surname></persName><roleName type="degree">M.D.</roleName><affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</affiliation></author></analytic><monogr><title level="j">American Heart Journal</title><title level="j" type="abbrev">YMHJ</title><idno type="pISSN">0002-8703</idno><idno type="PII">S0002-8703(00)X0653-9</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1982"></date><biblScope unit="volume">103</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="941">941</biblScope><biblScope unit="page" to="949">949</biblScope></imprint></monogr><idno type="istex">AE57E87DD3019AB099536DAB0AE539D3B5080899</idno><idno type="DOI">10.1016/0002-8703(82)90555-5</idno><idno type="PII">0002-8703(82)90555-5</idno><idno type="ArticleID">82905555</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1982</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Electrophysiologic drug testing was performed in nine patients with severely symptomatic sporadic (2 to 13 [mean 4.2] attacks/24 months) paroxysmal atrial fibrillation (PAF). All patients had control inductions of sustained (> 30 seconds) AF by high right atrial stimulation, and attempted inductions following serial administration of drugs. Drugs tested were intravenous procainamide (1.0 to 1.5 gm) (five patients), intravenous propranolol (0.1 mg/kg) (three patients), oral quinidine (1.6 to 2.4 gm/day) (six patients), oral disopyramide (1.2 to 1.6 gm/day) (four patients), and oral aprindine (100 to 250 mg/day) (four patients). In all patients, one or more drugs prevented induction of sustained AF: procainamide (one patient), quinidine (five patients), disopyramide (four patients), and aprindine (four patients). All patients were treated with drugs which prevented induction of sustained AF and followed for 8 to 40 (mean 24) months. Seven patients tolerated their drugs: six had no AF and one had several short nonsustained attacks. Two patients did not tolerate their drugs: one had paroxysmal palpitation (on decreased aprindine dosage), and one had AF (while off of aprindine). In conclusion, electrophysiologic drug testing is feasible in patients with sporadic PAF. Inability to induce sustained AF following drug administration suggests successful prophylaxis of spontaneous PAF with the same drug.</p></abstract><textClass><keywords scheme="keyword"><list><head>Article category</head><item><term>Clinical investigation</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1982-02-05">Registration</change><change when="1982">Published</change></revisionDesc></teiHeader></istex:fulltextTEI></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>YMHJ</jid><aid>82905555</aid><ce:pii>0002-8703(82)90555-5</ce:pii><ce:doi>10.1016/0002-8703(82)90555-5</ce:doi><ce:copyright type="unknown" year="1982"></ce:copyright><ce:doctopics><ce:doctopic><ce:text>Clinical investigation</ce:text></ce:doctopic></ce:doctopics></item-info><head><ce:article-footnote><ce:label>☆</ce:label><ce:note-para>Supported in part by National Heart, Lung and Blood Institute Institutional Training Grant HL 07387 and by Research Grants HL 18794 and HL 23566, and by a grant from the Eleanor B. Pillsbury Resident Trust Fund.</ce:note-para></ce:article-footnote><ce:title>Electrophysiologic drug testing in prophylaxis of sporadic paroxysmal atrial fibrillation: Technique, application, and efficacy in severely symptomatic preexcitation patients</ce:title><ce:author-group><ce:author><ce:given-name>Robert A.</ce:given-name><ce:surname>Bauernfeind</ce:surname><ce:degrees>M.D.</ce:degrees><ce:cross-ref refid="COR1"><ce:sup loc="post">∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Steven P.</ce:given-name><ce:surname>Swiryn</ce:surname><ce:degrees>M.D.</ce:degrees></ce:author><ce:author><ce:given-name>Boris</ce:given-name><ce:surname>Strasberg</ce:surname><ce:degrees>M.D.</ce:degrees></ce:author><ce:author><ce:given-name>Edwin</ce:given-name><ce:surname>Palileo</ce:surname><ce:degrees>M.D.</ce:degrees></ce:author><ce:author><ce:given-name>Daniel</ce:given-name><ce:surname>Scagliotti</ce:surname><ce:degrees>M.D.</ce:degrees></ce:author><ce:author><ce:given-name>Kenneth M.</ce:given-name><ce:surname>Rosen</ce:surname><ce:degrees>M.D.</ce:degrees></ce:author><ce:affiliation><ce:textfn>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Reprint requests: Robert A. Bauernfeind, M.D., Cardiology Section, University of Illinois Hospital, P.O. Box 6998, Chicago, IL 60680.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="8" month="1" year="1982"></ce:date-received><ce:date-accepted day="5" month="2" year="1982"></ce:date-accepted><ce:abstract class="author"><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para view="all" id="simple-para.0010">Electrophysiologic drug testing was performed in nine patients with severely symptomatic sporadic (2 to 13 [mean 4.2] attacks/24 months) paroxysmal atrial fibrillation (PAF). All patients had control inductions of sustained (> 30 seconds) AF by high right atrial stimulation, and attempted inductions following serial administration of drugs. Drugs tested were intravenous procainamide (1.0 to 1.5 gm) (five patients), intravenous propranolol (0.1 mg/kg) (three patients), oral quinidine (1.6 to 2.4 gm/day) (six patients), oral disopyramide (1.2 to 1.6 gm/day) (four patients), and oral aprindine (100 to 250 mg/day) (four patients). In all patients, one or more drugs prevented induction of sustained AF: procainamide (one patient), quinidine (five patients), disopyramide (four patients), and aprindine (four patients). All patients were treated with drugs which prevented induction of sustained AF and followed for 8 to 40 (mean 24) months. Seven patients tolerated their drugs: six had no AF and one had several short nonsustained attacks. Two patients did not tolerate their drugs: one had paroxysmal palpitation (on decreased aprindine dosage), and one had AF (while off of aprindine). In conclusion, electrophysiologic drug testing is feasible in patients with sporadic PAF. Inability to induce sustained AF following drug administration suggests successful prophylaxis of spontaneous PAF with the same drug.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Electrophysiologic drug testing in prophylaxis of sporadic paroxysmal atrial fibrillation: Technique, application, and efficacy in severely symptomatic preexcitation patients</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Electrophysiologic drug testing in prophylaxis of sporadic paroxysmal atrial fibrillation: Technique, application, and efficacy in severely symptomatic preexcitation patients</title></titleInfo><name type="personal"><namePart type="given">Robert A.</namePart><namePart type="family">Bauernfeind</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</affiliation><description>Reprint requests: Robert A. Bauernfeind, M.D., Cardiology Section, University of Illinois Hospital, P.O. Box 6998, Chicago, IL 60680.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Steven P.</namePart><namePart type="family">Swiryn</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Boris</namePart><namePart type="family">Strasberg</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Edwin</namePart><namePart type="family">Palileo</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Daniel</namePart><namePart type="family">Scagliotti</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kenneth M.</namePart><namePart type="family">Rosen</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine Chicago, Ill., USA.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1982</dateIssued><dateValid encoding="w3cdtf">1982-02-05</dateValid><copyrightDate encoding="w3cdtf">1982</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Electrophysiologic drug testing was performed in nine patients with severely symptomatic sporadic (2 to 13 [mean 4.2] attacks/24 months) paroxysmal atrial fibrillation (PAF). All patients had control inductions of sustained (> 30 seconds) AF by high right atrial stimulation, and attempted inductions following serial administration of drugs. Drugs tested were intravenous procainamide (1.0 to 1.5 gm) (five patients), intravenous propranolol (0.1 mg/kg) (three patients), oral quinidine (1.6 to 2.4 gm/day) (six patients), oral disopyramide (1.2 to 1.6 gm/day) (four patients), and oral aprindine (100 to 250 mg/day) (four patients). In all patients, one or more drugs prevented induction of sustained AF: procainamide (one patient), quinidine (five patients), disopyramide (four patients), and aprindine (four patients). All patients were treated with drugs which prevented induction of sustained AF and followed for 8 to 40 (mean 24) months. Seven patients tolerated their drugs: six had no AF and one had several short nonsustained attacks. Two patients did not tolerate their drugs: one had paroxysmal palpitation (on decreased aprindine dosage), and one had AF (while off of aprindine). In conclusion, electrophysiologic drug testing is feasible in patients with sporadic PAF. Inability to induce sustained AF following drug administration suggests successful prophylaxis of spontaneous PAF with the same drug.</abstract><note>Supported in part by National Heart, Lung and Blood Institute Institutional Training Grant HL 07387 and by Research Grants HL 18794 and HL 23566, and by a grant from the Eleanor B. Pillsbury Resident Trust Fund.</note><subject><genre>Article category</genre><topic>Clinical investigation</topic></subject><relatedItem type="host"><titleInfo><title>American Heart Journal</title></titleInfo><titleInfo type="abbreviated"><title>YMHJ</title></titleInfo><genre type="Journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">198206</dateIssued></originInfo><identifier type="ISSN">0002-8703</identifier><identifier type="PII">S0002-8703(00)X0653-9</identifier><part><date>198206</date><detail type="volume"><number>103</number><caption>vol.</caption></detail><detail type="issue"><number>6</number><caption>no.</caption></detail><extent unit="issue pages"><start>A5</start><end>A21</end></extent><extent unit="issue pages"><start>A87</start></extent><extent unit="issue pages"><start>941</start><end>1128</end></extent><extent unit="pages"><start>941</start><end>949</end></extent></part></relatedItem><identifier type="istex">AE57E87DD3019AB099536DAB0AE539D3B5080899</identifier><identifier type="DOI">10.1016/0002-8703(82)90555-5</identifier><identifier type="PII">0002-8703(82)90555-5</identifier><identifier type="ArticleID">82905555</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata><enrichments><istex:refBibTEI uri="https://api.istex.fr/document/AE57E87DD3019AB099536DAB0AE539D3B5080899/enrichments/refBib"><teiHeader></teiHeader><text><front></front><body></body><back><listBibl><biblStruct><monogr></monogr></biblStruct></listBibl></back></text></istex:refBibTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001559 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001559 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:AE57E87DD3019AB099536DAB0AE539D3B5080899
|texte= Electrophysiologic drug testing in prophylaxis of sporadic paroxysmal atrial fibrillation: Technique, application, and efficacy in severely symptomatic preexcitation patients
}}
| This area was generated with Dilib version V0.6.23. |  |